Post-marketing Pharmacovigilance And Medical Information Market (2026 - 2033)

Post-marketing Pharmacovigilance & Medical Information Market Summary

The global post-marketing pharmacovigilance and medical information market size was valued at USD 6.7 billion in 2025 and is projected to grow from USD 7.3 billion in 2026 to USD 13.8 billion by 2033, at a CAGR of 9.5% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of approximately 39.0% in 2025. Post-market surveillance, encompassing pharmacovigilance and the provision of medical information, is crucial for ensuring product safety, quality, and efficacy.

The growing demand for pharmaceuticals stems from the increasing elderly population and rising prevalence of chronic illnesses, such as diabetes, memory loss, heart disease, and osteoporosis, worldwide. The growing global geriatric population and rising prevalence of chronic diseases, such as diabetes, hypertension, dementia, cardiovascular diseases, and osteoporosis, are leading to increased demand for medications. This, in turn, is driving market growth as the elderly population requires more frequent medication and treatment. Moreover, government initiatives to improve healthcare infrastructure, pharmacovigilance services, and medical databases are also strengthening market growth.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The expansion of healthcare infrastructure, including the increasing number of hospitals, clinics, laboratories, and medical research centers, is catalyzing the demand for medications and medical devices globally. Another key driver of the market is the rising incidence of Adverse Drug Reactions (ADRs) and the incorporation of advanced ADR reporting tools. The growing number of ADRs, coupled with the adoption of improved ADR reporting technologies, is supporting market expansion.

The market is also driven by the outsourcing of pharmacovigilance operations and the introduction of cloud-based medical information systems. Leading players are focusing on outsourcing pharmacovigilance activities and introducing cloud-based systems for improved accuracy, cost efficiency, risk mitigation, and organizational agility. This shift towards outsourcing is revolutionizing the post-marketing pharmacovigilance market. Furthermore, the growing awareness among pharmaceutical staff of the importance of reporting adverse drug reactions and participating in pharmacovigilance is contributing to faster reporting and higher data quality in pharmacovigilance databases.

Analyst Perspective

The post-marketing pharmacovigilance and medical information market is witnessing steady growth owing to the increasing focus on drug safety, rising number of pharmaceutical and biologic product approvals, and stringent regulatory requirements for post-marketing surveillance. The market is experiencing growing adoption of artificial intelligence, automation, cloud-based pharmacovigilance platforms, and real-time adverse event monitoring as pharmaceutical companies seek to improve regulatory compliance, accelerate safety signal detection, and deliver timely, accurate medical information to healthcare professionals and patients. Although challenges such as evolving global regulatory requirements, increasing volumes of safety data, data privacy concerns, and the complexity of managing multi source information remain, continuous advancements in AI driven case processing, predictive analytics, and integrated pharmacovigilance systems are creating new growth opportunities.

Service Insights

The spontaneous reporting service segment dominated the post-marketing pharmacovigilance and medical information market, accounting for around 35.0% of revenue in 2025. Real-time data collection, early detection of adverse events, and broad accessibility enable pharmacovigilance systems to dominate the market. Compliance with regulatory requirements, signal detection, and risk management capabilities contribute to its success. Spontaneous reporting services facilitate the rapid identification of adverse events, enabling timely detection of new risks and helping ensure drug safety.

The cohort event monitoring service segment is expected to register the fastest growth over the forecast period. Cohort event monitoring provides a proactive approach to tracking unfavorable activities in patients receiving specific medications or vaccines. This methodology involves enrolling patient cohorts, collecting real-world data through observational studies and post-marketing surveillance, and analyzing longitudinal trends to inform treatment decisions. Insights gained from this approach enable healthcare professionals to make more informed choices.

End-use Insights

The hospital segment dominated the post-marketing pharmacovigilance and medical information market with a revenue share of over 60.0% in 2025. The industry’s dominance is driven by the need for enhanced patient safety, regulatory compliance, and the growing demand for evidence-based medicine. Hospitals prioritize patient safety by investing in robust post-marketing pharmacovigilance and medical information systems, enabling healthcare professionals to identify, monitor, and assess potential drug side effects, ultimately ensuring high-quality care with minimal risks.

The research organization segment is expected to register the fastest CAGR over the forecast period. The growth can be attributed to the organization’s expertise, global reach, regulatory partnerships, innovative thinking, and adaptability, enabling them to drive change. Leveraging advanced technology and connections to physicians, they efficiently monitor drug safety, collecting, analyzing, and disseminating data. This enables research teams to manage vast amounts of information while ensuring compliance with regulatory requirements.

Regional Insights

The North America post-marketing pharmacovigilance and medical information market dominated the global market, accounting for around 39.0% of revenue in 2025. The region’s dominance can be attributed to its strong regulatory framework, cutting-edge technology, substantial market size, and highly skilled workforce. In addition, the well-established healthcare system and expert professionals in the region are driving growth further, as they provide high-quality services and foster innovation. This combination of factors enables the organization to maintain its competitive edge.

To learn more about this report, Download Free Sample Report

U.S. Post-marketing Pharmacovigilance & Medical Information Market Trends

The U.S. accounted for over 78.0% of the post-marketing pharmacovigilance and medical information market in North America. The U.S. is at the forefront of technological innovation, leveraging advanced data analytics, AI, and advanced systems expertise to drive drug safety monitoring. This tech advantage enables American companies to deliver premium solutions for tracking adverse reactions and analyzing real-world data, setting them apart in the global market.

Europe Post-marketing Pharmacovigilance & Medical Information Market Trends

The Europe post-marketing pharmacovigilance and medical information market represented a substantial share of the global market in 2025. Europe has a strong regulatory framework for pharmacovigilance, with organizations such as the European Medicines Agency (EMA) playing a key role in monitoring the protection of drugs put up and approved. The stringent guidelines and reporting requirements in Europe have contributed to constructing a culture of pharmacovigilance excellence within the region.

The post-marketing pharmacovigilance and medical information market in Germany is expected to grow over the forecast period. Germany has a top-notch healthcare system with cutting-edge facilities, state-of-the-art tech, and skilled medical staff. This setup has an impact on making pharmacovigilance work and allows for quick gathering, study, and sharing of drug safety data.

The UK post-marketing pharmacovigilance and medical information market held a substantial market share in 2025. The UK has a robust regulatory framework for pharmacovigilance, with agencies such as the Medicines and Healthcare Products Regulatory Agency (MHRA) overseeing drug protection monitoring and reporting. The stringent regulations ensure that pharmaceutical companies operating in the UK adhere to high standards of pharmacovigilance practices.

Asia Pacific Post-marketing Pharmacovigilance & Medical Information Market Trends

Asia Pacific is anticipated to witness the fastest growth during the forecast period, driven by the rapid expansion of the region's pharmaceutical industry. The presence of a large and diverse patient population offers significant opportunities for pharmaceutical companies, while the availability of cost-effective pharmacovigilance and medical information services further strengthens regional market growth.

The China post-marketing pharmacovigilance and medical information market is expected to experience robust growth throughout the forecast period, supported by increasingly stringent regulatory frameworks aimed at ensuring the safety and efficacy of pharmaceutical products after commercialization. Coupled with its large population, expanding healthcare infrastructure, and growing pharmaceutical sector, these factors are driving demand for post-marketing pharmacovigilance and medical information services.

The India post-marketing pharmacovigilance and medical information market accounted for a significant share of the Asia Pacific market in 2025. The country has established itself as a leading destination for pharmacovigilance and medical information outsourcing due to its cost-efficient service offerings, strong talent pool of skilled healthcare and life sciences professionals, and well-developed outsourcing ecosystem. These advantages continue to attract global pharmaceutical companies seeking high-quality, cost-effective post-marketing safety and medical information support.

Key Post-marketing Pharmacovigilance & Medical Information Market Companies Insights

Some key companies in the post-marketing pharmacovigilance and medical information market include IQVIA Inc., Parexel International (MA) Corporation, Laboratory Corporation of America Holdings., and ICON plc. Organizations are focusing on increasing customer base to gain a competitive edge in the industry. The key players are taking several strategic initiatives, such as mergers and acquisitions, and partnerships with other major companies. 

• IQVIA Inc., a provider of superior analytics, technological solutions, and medical research services to the life sciences industry, focuses on developing intelligent connections across all elements of healthcare. The company focuses on the scientific improvement and commercialization of modern scientific remedies that enhance healthcare outcomes for patients.

Key Post-marketing Pharmacovigilance & Medical Information Companies

The following key companies have been profiled for this study on the post-marketing pharmacovigilance and medical information market:

• IQVIA Inc

• Parexel International (MA) Corporation

• Laboratory Corporation of America Holdings

• ICON plc

• Accenture

• Cognizant

• F. Hoffmann-La Roche Ltd

• Sanofi

• ArisGlobal

• Ergomed Group

• Medpace

• IBM Corporation

• Wipro

• Capgemini

Recent Developments

• In January 2026, ArisGlobal announced enhancements to its LifeSphere platform, including NavaX Agents, NavaX Insights, and LifeSphere Unify, aimed at strengthening AI-driven pharmacovigilance, regulatory compliance, and medical information management. The new capabilities support real-time safety analytics, automated case processing, and integrated data management across safety, regulatory, quality, and medical affairs functions.

• In January 2025, IQVIA and NVIDIA announced an expanded collaboration to accelerate AI adoption across the life sciences industry. The partnership combines IQVIA's healthcare-grade AI capabilities with NVIDIA AI Foundry technologies to enhance pharmacovigilance, regulatory workflows, and medical information management through advanced AI-driven solutions.

Global Post-marketing Pharmacovigilance & Medical Information Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global post-marketing pharmacovigilance and medical information market report on the basis of service, end-use, and region:

• Service Outlook (Revenue, USD Billion, 2021 - 2033)
  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining
• End-use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospitals
  • Research Organizations
  • Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait